Publications by authors named "S Hige"
Tenofovir alafenamide (TAF), a prodrug of tenofovir, delivers high levels of active drug to hepatocytes and is given in a lower dose than tenofovir disoproxil fumarate (TDF). TAF reduces viral replication in patients with chronic hepatitis B (CHB) similar to TDF and has shown a lower risk of the renal and bone toxicities associated with TDF use. This post-marketing surveillance study examined the safety and effectiveness of TAF in treatment-naïve and -experienced CHB patients who received TAF for 144 weeks at real-world clinical sites in Japan.
View Article and Find Full Text PDFCell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
Hepatol Res
March 2023
Article Synopsis
- The study compares the effectiveness of cell-free and concentrated ascites reinfusion therapy (CART) and large-volume paracentesis (LVP) with albumin infusion in treating refractory ascites (RA) in patients with cirrhosis.
- From June 2018 to March 2022, 25 patients were monitored for treatment outcomes, focusing on the number of paracenteses, drainage volume, and albumin use over 8 weeks.
- Results showed that while CART required fewer paracenteses and albumin infusions, there were no significant differences in overall treatment effectiveness, suggesting both therapies are equally beneficial for managing RA.
Article Synopsis
- Hepatitis B virus (HBV) is a widespread chronic infection in Japan, predominantly involving genotypes B and C, but there's been a gradual increase in genotype A cases over the years.
- A nationwide survey included 4,421 chronic hepatitis B (CHB) patients to analyze the distribution of HBV genotypes and their trends across different age groups from 2000-2016.
- Results showed that while the overall prevalence of genotype A remained stable, it rose among younger adults; meanwhile, genotypes B and C shifted to older populations, highlighting the need for future studies on the impact of Japan's universal HBV vaccination introduced in 2016.
Background: Rifaximin is commonly used for hepatic encephalopathy (HE). However, the effects of long-term treatment for Japanese people are limited. Therefore, this study aimed to investigate the effects and safety of long-term treatment with rifaximin on HE.
View Article and Find Full Text PDFIntroduction And Objectives: Sustained virologic response (SVR) is achieved in most cases of C-type liver disease after direct-acting antiviral (DAA) therapy. Although liver fibrosis improves, the degree of improvement is different. This study aimed to analyze the factors involved in improving liver fibrosis using the fibrosis 4 (FIB-4) index.
View Article and Find Full Text PDF